PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21871559-5	2011	Low tert-butylhydroperoxide (tBH) concentrations similarly mediated promoter activation, but the maximal activation dose was decreased 10-fold by insulin.	tert-Butylhydroperoxide	4-27	insulin	Homo sapiens	146-153	
21871559-5	2011	Low tert-butylhydroperoxide (tBH) concentrations similarly mediated promoter activation, but the maximal activation dose was decreased 10-fold by insulin.	tert-Butylhydroperoxide	29-32	insulin	Homo sapiens	146-153	
21871559-6	2011	Insulin-tBH coadministration abrogated the low or high glucose requirement for promoter activation, suggesting possible ROS involvement.	tert-Butylhydroperoxide	8-11	insulin	Homo sapiens	0-7	
18926903-4	2008	However, on tert-butylhydroperoxide challenge, insulin-treated cells demonstrated a robust GSH recovery that was attributed to a greater capacity for de novo synthesis via elevated GCLc levels.	tert-Butylhydroperoxide	12-35	insulin	Homo sapiens	47-54	
7533613-16	1995	The intracellular "hydroperoxide donor" tert-butylhydroperoxide in the concentration range of 0.03-3 mM inhibited insulin release stimulated by the nutrient secretagogues glucose and L-arginine.	tert-Butylhydroperoxide	40-63	insulin	Homo sapiens	114-121	
7533613-24	1995	The mechanism underlying the secretion promoting action of tert-butylhydroperoxide on IBMX-induced insulin release is probably linked to intracellular Ca2+-perturbations affecting exocytosis.8.	tert-Butylhydroperoxide	59-82	insulin	Homo sapiens	99-106	
4460-7	1976	Tert-butyl hydroperoxide (2 X 10(-3) M), a glutathione-oxidizing reagent, inhibited degradation by 35 to 50%, possibly due to an effect on a glutathione-insulin transhydrogenase.	tert-Butylhydroperoxide	0-24	insulin	Homo sapiens	153-160